Our Research

Click on the links for the latest information on any of these trials OR new concepts in development.

Download the ALTG Research Report 2004 – 2016

 

Active Trials – Recruiting or in Study Start-Up

The following ALTG trials are recruiting or in the study start-up stage

Trial  Number Title More Information
ALTG 14/001
BR.31
A phase III prospective double-blind placebo-controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancerRECRUITING
ANZCTR record
ALTG 15/003
DREAM
A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma with a safety run inRECRUITING
ANZCTR record
ALTG 14/002
NIVORAD
A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer progressing after first or second line chemotherapyRECRUITING
ANZCTR record
ALTG 13/008
PEARL
A randomised phase 2 trial of early referral to palliative care for patients with advanced thoracic malignanciesSTUDY START-UP
ANZCTR record
ALTG 16/005
OSCILLATE
Alternating Osimertinib and Gefitinib in patients with EGFR T790M postive NSCLCSTUDY START-UP
ALTG 16/004
SCRIBE
A phase 2 study of nivolumab with radiotherapy or nivolumab with ipilimumab in the treatment of small cell lung cancer brain metastasesSTUDY START-UP

Trials In Follow Up (closed to recruitment)

Currently there are no ALTG trials in the follow-up stage

Trial  Number Title Information Link

Cobadged/ Endorsed Trials

The following trials have been endorsed by the ALTG

Trial  Number Title More Information
ALTG 16/013
(ANZ LCNF)
Activities and influence of the specialist lung cancer nurseIN DEVELOPMENT
ALTG 16/011 TROG 16.03
CORE
Conventional care Or Radioablation for Extracranial metastasesSTUDY START-UP
ALTG 15/001 TD 13.03
SABR-OS
A randomised phase 2 trial to test the feasibility of randomising patients with peripheral stage I NSCLC to either Stereotactic Ablative Radiotherapy (SABR) Or SurgeryIN DEVELOPMENT
ALTG 13/004
OPAL
On-line and Phone Assistance for Lung cancer patientsRECRUITING
ANZCTR record
ALTG 13/003
Rekindle
Testing an online resource to promote sexual wellbeing for both patients and their partnersRECRUITING
ANZCTR record
ALTG 13/002Health related quality of life (HQoL) in malignant mesotheliomaRECRUITING
ALTG 13/001
TROG 13.01 SAFRON II
Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung: a randomised phase 2 trialRECRUITING
ANZCTR record
ATLG 12/003
CUMM
Chemotherapy Utilisation for Malignant MesotheliomaCOMPLETED
Kao et al Asia Pac J Clin Oncol 2015
ALTG 10/001 TROG 11.03
PLUNG-GP
Randomised phase 3 trial of high dose palliative radiotherapy (HDPRT) vs concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/ small volume metastatic NSCLC not suitable for radical chemo-radiotherapyRECRUITING
ANZCTR record
ALTG 09/005
TROG 09.02 CHISEL
Hypofractionated image guided radiotherapy ("stereotactic") versus conventional radiotherapy for inoperable early stage I NSCLCIN FOLLOW-UP
ALTG 08/001 PA in Lung (PAL)Physical Activity in Lung cancer patientsPUBLISHED
Dhillon et al Annals of Oncology 2017

Completed/Closed Trials

Trial  Number Title More Information
ALTG 04/001Randomized comparison of first line docetaxel/gemcitabine doublet chemotherapy versus sequential single agent chemotherapyPublished
P-554 Randomized Phase II study of first-line docetaxel (D)/ gemcitabine (G) doublet chemotherapy versus fixed duration (3 cycles) sequential single agent chemotherapy (D then G) in Stage IIIB/IV non-small cell lung cancer (NSCLC)—Final Results. A study by the NSW and Australian Lung Cancer Trials Group
Pavlakis, N. et al.
Lung Cancer , Volume 49 , S263
ALTG 04/003MATES - Maintenance Thalidomide in Mesothelioma PatientsPublished
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study
Buikhuisen, Wieneke A et al.
The Lancet Oncology , Volume 14 , Issue 6 , 543 - 551
ALTG 04/009PACT - Lung Cancer Patient PreferencesMoth et al. Lung Cancer 2016
ALTG 06/003NITRO: A randomised, phase III trial of adding nitroglycernin to first line chemotherapy in advanced non-small cell lung cancer.Davidson et al Ann Oncol 2015
ALTG 09/001BR29Published
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29
Laurie, S.A. et al.
European Journal of Cancer , Volume 50 , Issue 4 , 706 - 712
ALTG 09/002BR26Ellis et al Lancet Oncol 2014
ALTG 09/004B2P2M2Nowak et al Lung Cancer 2013
ALTG 10/002A Pilot Study To Develop A Classification Algorithm For Identifying Patients With Adenocarcinoma Of Lung Suitable For Individualized TherapiesStudy completed late 2011
ALTG 10/003Implementing standardised PET procedures for scanning, data collection and reporting in patients with NSCLC across Australia’s ALTG sites: A feasibility study.Study completed late 2011
ALTG 10/004Limiting the functional decline of patients with advanced non-small cell lung cancer.Study completed
Upcoming Events
  1. TACT Board Teleconference (closed)

    August 28 - August 29
  2. ESMO 2017 Congress, Madrid Spain

    September 8 - September 12
  3. ***UPDATED*** 3rd ALTG Preceptorship in Lung Cancer, Melbourne VIC

    September 22 @ 12:00 pm - September 23 @ 5:00 pm UTC+10
  4. TACT General Assembly (closed), Yokohama Japan

    October 15
  5. 18th WCLC, Yokohama Japan

    October 15 - October 18